ORIC PHARMACEUTICALS INC (ORIC)
Health Care · Oncology / targeted cancer therapeutics · NASDAQ
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
What ORIC PHARMACEUTICALS INC does
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. The company is advancing two lead product candidates: rinzimetostat (formerly ORIC-944) and enozertinib (formerly ORIC-114), both in clinical development. ORIC focuses on identifying and developing therapeutics that address unmet medical needs in oncology through precision medicine approaches.
Themes: ["Oncology / cancer therapeutics"]
Fundamentals
- Price$10.94 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+0.4% as of 2026-07-09 close
- ROE-35.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.94 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial failure risk — the ability of clinical trials to demonstrate safety and efficacy for rinzimetostat, enozertinib and other candidates is uncertain and central to regulatory approval and commercialization."]
Competitors & peers
- Genentech / Roche
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.